Why BGPT?
logo

Assess an author's data and outputs

See the raw experimental evidence behind an author's publications and reproducibility signals.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Explanation


    Emmanuel Mignot (narcolepsy/hypocretin–orexin genetics & translational models) appears to have a strong scientific footprint in the biological mechanisms of narcolepsy and its biomarkers—especially via immunogenetic/HLA and orexin/hypocretin-centered lines of work—while some mechanistic questions (e.g., “is X neuron marker also functionally essential?”) remain sensitive to model choice, phenotype detectability, and proxy endpoints.



     Long Explanation


    Author Review (Scientific Strength): Emmanuel Mignot

    Scope note (critical): This review only uses the information explicitly provided in your prompt (paper titles/DOIs provided in the “research data” block + selected OpenAlex top works metadata) and does not infer missing details. Where mechanistic conclusions are probabilistic, I distinguish known vs inferred vs uncertain.

    1) Quick visual: what themes show up in the provided paper set?

    Based on the explicit DOIs/titles you included in the prompt, the dominant biological axes here are narcolepsy biology (orexin/hypocretin deficiency; HLA genetics; autoimmunity framing) and neurobiology of hypothalamic histaminergic systems (TM/peripherin marker/fn question).

    2) Citation footprint (as provided in your prompt)

    Your prompt includes two different citation-metric snapshots: (i) a small “Author Citation Information” (h-index=1; total citations=22; 5 papers) and (ii) an “OpenAlex Author Information” match list that includes an Emmanuel Mignot ORCID record with much larger bibliometrics.

    Critical interpretation: bibliometric identity resolution (same-name ambiguity, multiple ORCIDs, and partial author disambiguation) can materially change the metric values. Because these metric blocks lack DOIs, I treat them strictly as provided metadata, not as verifiable external measurements.

    3) Strengths in mechanistic biology (with evidence grading)

    3.1 HLA genetics & age-of-onset effects in narcolepsy
    A recurring Mignot-centered theme in the provided metadata is that HLA class II alleles strongly influence narcolepsy risk and timing. For example, your prompt includes a study where HLA-DQB1*03:01 affects age of onset of type 1 narcolepsy independently of DQA1 and ethnicity (title given in your paper list; exact DOI not provided there).

    In the supplied OpenAlex “top works” list, Mignot is included as an author on papers examining hypocretin/orexin deficiency and diagnostic biology (e.g., a Lancet letter on hypocretin deficiency) and on immunogenetic contributions. This is consistent with a research program aimed at quantifying genotype–phenotype structure in orexin/hypocretin loss.

    Evidence type sensitivity: HLA association studies are robust for describing statistical risk structure, but causal inference depends on linkage disequilibrium, population stratification handling, and functional follow-through.
    3.2 Biomarker-centered narcolepsy diagnosis biology
    The prompt includes: “The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias” with DOI 10.1001/archneur.59.10.1553. Such work is typically valuable because it constrains the diagnostic mapping between CSF hypocretin levels and clinical phenotypes.

    Known vs uncertain: It is generally “known” (within narcolepsy field consensus) that CSF hypocretin deficiency is strongly associated with type 1 narcolepsy; however, threshold generalization across labs and assay versions and edge-case clinical phenotypes are often less certain and need careful external validation.
    3.3 TM (tuberomammillary) neuron biology and the “marker vs function” problem (peripherin)
    One of the provided research-data blocks is mechanistically oriented: peripherin (a type III neurofilament) is expressed in TM histaminergic neurons, but changing peripherin does not obviously produce neuroanatomical/metabolic/sleep phenotypes.

    The key scientific rigor signal here is that the study does both: (i) uses expression localization (ISH/ICC) to show colocalization and (ii) performs genetic perturbations (KO and overexpression; also hypocretin-ataxin background validation for proxy methods) to test functional consequences.

    But: absence of detectable phenotype is hard to interpret without sensitivity analysis (assay endpoint limitations, compensatory neurofilament redundancy, and proxy sleep estimation vs polysomnography).

    4) “Phrasing/translation” quality: pharmacology syntheses & model-to-human bridging

    Your prompt includes a narrative pharmacology review/synthesis with DOI 10.1016/S0301-0082(96)00070-6 (Progress in Neurobiology; late 1990s perspective). Reviews can be scientifically useful for consolidating mechanistic hypotheses and translational directions, but they are inherently limited in reproducibility because they may pool heterogeneous study designs, endpoints, and assay paradigms.

    5) Evidence-based skepticism: key blind spots suggested by the provided materials

    • Sample-size & model-selection risk: The TM/peripherin work includes baseline phenotyping and uses LMA-based sleep proxies; without polysomnographic confirmation, subtle sleep architecture effects could be missed. (Derived from your provided limitations in the peripherin extraction.)
    • Association ≠ mechanism: HLA association frameworks are powerful for risk stratification, but causal mechanism typically requires functional immunology/audiology-type follow-through (antigen presentation mapping, T-cell assays, etc.). The prompt provides no such functional immunology data here, so mechanistic certainty should remain moderate.
    • Industry/sponsor bias possibility: The pharmacology synthesis extraction explicitly notes partial Cephalon funding. Reviews should still be evaluated for how they handle contradictory evidence and negative findings.

    6) Visual: “study design strength” snapshot from provided works

    I’m not grading the author here; I’m grading the evidence type implied by each provided work (genetics/diagnosis/functional perturbation vs narrative synthesis) as a proxy for what each study can reliably establish.
    This proxy is deliberately conservative and reflects only what was described in your prompt (evidence type + limitations). It should not be treated as a formal systematic review.

    7) Net assessment (scientific strength, with calibrated confidence)

    Most supported strengths (from provided materials):
    • Biomarker + genotype mapping in narcolepsy biology is repeatedly evidenced by CSF hypocretin diagnostic work and HLA-linked risk/timing themes.
    • Mechanistic testing exists in at least one provided neurobiology example: expression localization + genetic perturbation + endpoint assessment.
    Key uncertainty: With the subset of works explicitly provided here, I can’t fully reconstruct the author’s broader experimental track record across decades or across multiple systems—only the themes and evidence types shown above. Identity-disambiguation ambiguity in bibliometric blocks adds further uncertainty about which “Emmanuel Mignot” subset corresponds to the exact same individual across all metrics.


    Feedback:    

    Updated: May 02, 2026

     Top Data Sources ExportMCP


     Hypothesis Graveyard


    “Peripherin is essential for TM neuron function under baseline conditions” is weakened by the provided peripherin KO/TG results showing no obvious phenotype in anatomy/metabolic/locomotor proxy endpoints.


    “Narrative pharmacology syntheses fully resolve mechanism and predict all drug effects across species” is unlikely because the provided extraction explicitly flags heterogeneity, proxy endpoints, species differences, and potential sponsor bias in review-era evidence consolidation.

     Science Art


    Author Review: Emmanuel Mignot Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending